GlassScriptPhysician profile
Charles E Sherman
NPI 1851328579
$1,132.46
in general payments reported to CMS, 2019-2025
22 companies · $41.03 in 2025
The $41.03 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $24.54 · 2021: $363 · 2022: $287 · 2023: $37.66 · 2025: $41.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $125.46 | 2019-2021 | |
| Abbvie INC. | $98.87 | 2021-2023 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $72.49 | 2021-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $62.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.74 | 2022-2025 | |
| Pfizer INC. | $56.50 | 2019-2023 | |
| Amgen INC. | $49.08 | 2019-2021 | |
| Amarin Pharma, INC. | $41.09 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.14 | 2022 | |
| Glaxosmithkline, LLC. | $38.68 | 2019-2021 | |
| Biomerieux INC | $37.00 | 2019 | |
| Dexcom, INC. | $31.94 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $29.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.81 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.97 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.73 | 2019 | |
| Shire North American Group INC | $16.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2019 | |
| Astellas Pharma US INC | $15.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.